ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,575.90
-1.39%
S&P ASX All Technology
2,970.40
-1.25%
Brent Oil
88.165
0.00%
US Dollar vs AUD
1.53139
0.00%
Bitcoin
63,537.18
0.20%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
25/04/202422:00PR Newswire (US)AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AZNAstraZeneca PLC
25/04/202421:53IH Market NewsU.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy ForecastNASDAQ:AZNAstraZeneca PLC
25/04/202421:52IH Market NewsSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on EarningsNASDAQ:AZNAstraZeneca PLC
25/04/202416:00Business WireQ1 2024 resultsNASDAQ:AZNAstraZeneca PLC
16/04/202421:00Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trialNASDAQ:AZNAstraZeneca PLC
12/04/202421:05IH Market NewsParamount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202421:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:AZNAstraZeneca PLC
11/04/202421:00Business WireFASENRA approved for treatment of children aged 6 to 11 with severe asthmaNASDAQ:AZNAstraZeneca PLC
06/04/202414:10Business WireENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid TumorsNASDAQ:AZNAstraZeneca PLC
06/04/202412:43Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumorsNASDAQ:AZNAstraZeneca PLC
05/04/202422:00Business WireIMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trialNASDAQ:AZNAstraZeneca PLC
02/04/202422:00Business WireDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancerNASDAQ:AZNAstraZeneca PLC
02/04/202417:00Business WireDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast CancerNASDAQ:AZNAstraZeneca PLC
01/04/202422:00Business WireVOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNHNASDAQ:AZNAstraZeneca PLC
27/03/202421:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNASDAQ:AZNAstraZeneca PLC
26/03/202422:20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNASDAQ:AZNAstraZeneca PLC
25/03/202422:00Business WireULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)NASDAQ:AZNAstraZeneca PLC
19/03/202422:33IH Market NewsUnilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and MoreNASDAQ:AZNAstraZeneca PLC
19/03/202422:00Business WireAstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancerNASDAQ:AZNAstraZeneca PLC
19/03/202421:52IH Market NewsAstraZeneca to acquire Fusion for $2 billionNASDAQ:AZNAstraZeneca PLC
18/03/202422:00Business WireAstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolioNASDAQ:AZNAstraZeneca PLC
14/03/202422:39IH Market NewsFisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase InitiativeNASDAQ:AZNAstraZeneca PLC
13/03/202422:06Business WireAstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPDNASDAQ:AZNAstraZeneca PLC
07/03/202421:43IH Market NewsTesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak ForecastNASDAQ:AZNAstraZeneca PLC
27/02/202408:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
27/02/202401:00PR Newswire (Canada)Alexion Canada donne de la couleur aux maladies rares avec la campagne internationale colourUp4RARENASDAQ:AZNAstraZeneca PLC
27/02/202401:00PR Newswire (Canada)Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE CampaignNASDAQ:AZNAstraZeneca PLC
26/02/202422:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
24/02/202408:09Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:AZNAstraZeneca PLC
24/02/202405:23Business WireMANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRANASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

NASDAQ
AAPL
Apple
ASX
SUN
Suncorp
ASX
QBE
QBE Insurance
NASDAQ
TSLA
Tesla
NASDAQ
AMZN
Amazon.com
ASX
ORG
Origin Energy
ASX
XAO
Australian SE All Ordina...
FX
AUDCAD
AUD vs CAD
ASX
WOW
Woolworths
FX
AUDUSD
AUD vs US Dollar
NYSE
NKE
Nike
ASX
XTO
S&P ASX 100
ASX
WDC
Westfield
PM
XAUUSD
Gold vs US Dollar
ASX
ANZ
Australia And New Zealan...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved